Tpg Gp A, Llc Sells 202,368 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) major shareholder Tpg Gp A, Llc sold 202,368 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $20.12, for a total transaction of $4,071,644.16. Following the transaction, the insider owned 3,765,054 shares in the company, valued at approximately $75,752,886.48. This trade represents a 5.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

CeriBell Stock Performance

NASDAQ:CBLL traded down $0.51 during trading hours on Tuesday, reaching $19.45. 505,081 shares of the company’s stock were exchanged, compared to its average volume of 326,752. The firm has a market capitalization of $737.93 million, a price-to-earnings ratio of -11.93 and a beta of 0.85. The company has a 50-day moving average of $18.90 and a 200 day moving average of $19.74. The company has a quick ratio of 10.01, a current ratio of 10.44 and a debt-to-equity ratio of 0.14. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $24.33.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The business had revenue of $26.49 million during the quarter, compared to analyst estimates of $26.09 million. Research analysts anticipate that CeriBell, Inc. will post -1.69 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its position in CeriBell by 15.3% in the first quarter. Bank of America Corp DE now owns 319,837 shares of the company’s stock valued at $5,863,000 after purchasing an additional 42,340 shares during the period. Quantinno Capital Management LP increased its position in CeriBell by 3.0% during the 1st quarter. Quantinno Capital Management LP now owns 140,347 shares of the company’s stock worth $2,573,000 after purchasing an additional 4,119 shares during the period. Sei Investments Co. increased its position in CeriBell by 2.3% during the 1st quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after purchasing an additional 1,125 shares during the period. State of Wyoming purchased a new position in shares of CeriBell during the 1st quarter worth approximately $62,000. Finally, KCM Capital Inc lifted its holdings in shares of CeriBell by 40.0% in the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock valued at $25,662,000 after buying an additional 400,000 shares during the period.

Analyst Ratings Changes

A number of research firms have weighed in on CBLL. Weiss Ratings cut CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, June 12th. Canaccord Genuity Group cut their price target on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.20.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.